CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
However, the placebo group also saw a 1.98-point in ... Along with LSR, Vertex is also running a trial of suzetrigine in painful diabetic peripheral neuropathy (DPN), another form of chronic ...
Investor's Business Daily on MSN1d
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy PointBiotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...
Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
The Reserve Bank would like to state that the bank is well-capitalised and the financial position of IndusInd Bank remains ...
Nvidia (NVDA) CEO Jensen Huang took to the stage Tuesday afternoon to deliver his keynote speech at the chip giant's 2025 GTC event (GPU Technology Conference), where he previewed the company's ...
Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...
Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) ("Skyharbour" or the "Company"), is pleased to announce that its partner company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback